4-(4-fluorophenyl)-2-(trifluoromethyl)oxazole-5-carboxylic acid | 1422175-36-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-fluorophenyl)-2-(trifluoromethyl)oxazole-5-carboxylic acid
• 英文别名: 4-(4-Fluorophenyl)-2-(trifluoromethyl)oxazole-5-carboxylic acid；4-(4-fluorophenyl)-2-(trifluoromethyl)-1,3-oxazole-5-carboxylic acid
• CAS: 1422175-36-7
• 化学式: C₁₁H₅F₄NO₃
• 分子量: 275.159
• InChiKey: SZVZENGOCYSAFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-(4-fluorophenyl)-2-(trifluoromethyl)oxazole-5-carboxylic acid 、 1-(3-氯苯基)哌嗪 在 N-甲基吗啉 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 正丁醇 为溶剂， 反应 1.0h， 生成 [4-(3-chlorophenyl)piperazin-1-yl][4-(4-fluorophenyl)-2-(trifluoromethyl)oxazol-5-yl]methanone
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy

  摘要：

  A series of aryloxazole, thiazole, and isoxazole derivatives was synthesized as vascular-targeting anticancer agents. Antiproliferative activity and tumor vascular-disrupting activity of all of the synthesized compounds were tested in vitro using various human cancer cell lines and HUVECs (human umbilical vein endothelial cells). Several compounds with an arylpiperazinyl oxazole core showed excellent cytotoxicity and metabolic stability in vitro. Among this series, two representative compounds (6-48 and 6-51) were selected and tested for the evaluation of anticancer effects in vivo using tumor-bearing mice. Compound 6-48 effectively reduced tumor growth (42.3% reduction in size) at the dose of 100 mg/kg. We believe that compound 6-48 will serve as a good lead compound for antimitotic and vascular-disrupting agents; further investigation to improve the in vivo efficacy of this series is underway.

  DOI：

  10.1021/jm400840p
• 作为产物：
  描述：

  4-氟苯甲酰乙酸甲酯 在 ammonium acetate 、 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 23.0h， 生成 4-(4-fluorophenyl)-2-(trifluoromethyl)oxazole-5-carboxylic acid
  参考文献：
  名称：

  [EN] PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS
  [FR] PRÉPARATION ET PROCÉDÉS D'UTILISATION D'ORTHO-ARYLE HÉTÉROARYLE À 5 CHAÎNONS -CARBOXAMIDE CONTENANT DES INHIBITEURS DE KINASES MULTICIBLES

  摘要：

  本公开涉及式(I)的化合物及其药用可接受盐，作为激酶调节剂，与激酶的II型抑制相兼容。

  公开号：

  WO2013022766A1

文献信息

• PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS
  申请人：Flynn Gary A.

  公开号：US20140228367A1

  公开（公告）日：2014-08-14

  The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.

  本公开涉及式（I）的化合物及其药学上可接受的盐，作为酶调节剂，与激酶的II型抑制相兼容。
• Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
  申请人：Flynn Gary A.

  公开号：US09221805B2

  公开（公告）日：2015-12-29

  The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.

  本公开涉及公式（I）的化合物以及药学上可接受的盐，作为激酶调节剂，与激酶的二型抑制相兼容。
• PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS
  申请人：Flynn, Gary, A.

  公开号：EP2739143B1

  公开（公告）日：2018-07-11
• US9221805B2
  申请人：——

  公开号：US9221805B2

  公开（公告）日：2015-12-29
• US9833455B2
  申请人：——

  公开号：US9833455B2

  公开（公告）日：2017-12-05